Cancer treatments are currently being provided to patients in much the same way as they have been for the past two decades. Luckily, there is a new Company in town that is focusing on using disruptive technologies to change the game.Co-founder of Groupon, Eric Lefkofsky, recently created Tempus, a health technology company focusing on machine learning and genome sequencing. This firm recently announced its partnership with the University of Chicago Medicine to try and create specific cancer treatments for patients based on their genetic makeup. This firm will use molecular sequencing and analysis to determine which treatments provide the optimal cancer-fighting power for each individual patient, giving them all of the benefits of cancer treatment without some of the nasty side-effects. Doctors, patients, and technology firms everywhere are hoping that these treatments are the new wave of disruptive technology that will end cancer once and for all.
Eric Lefkofsky is no stranger to disruptive technologies. In fact, many would say that he is one of the foremost experts in disruptive tech in the upper Midwest. Eric has created several different companies that focus on technology and their delivery to the consumer or organizations, including Echo Global Logistics, Mediaocean, Uptake Technologies, Tempus, and Lightbank. With this suite of companies, he has shown that he knows about entrepreneurship and disruptive technologies, and he is showing no signs of stopping the advancement of technologies.
Lefkofsky is also founder of the Lefkofsky Family Foundation, a private charitable foundation focusing on organizations and projects in the Chicago area. He is also the trustee of several different organizations, including the Children’s Hospital of Chicago and the Museum of Science and Industry. Lefkofsky is also a professor at the University of Chicago, and has been a professor of applied technology and disruptive business modeling at DePaul University and Northwestern University.